The Bailey lab focuses on developing gene therapies for neurological disorders. We work on monogenetic pediatric disorders, including SLC13A5 epileptic encephalopathy, multiple sulfatase deficiency, Charcot Marie Tooth disease type 4J, giant axonal neuropathy and ECHS1 deficiency.
At the Center for Alzheimer’s and Neurodegenerative Diseases, we are developing approaches that bring adeno-associated virus to bear on more complex, non-inherited neurodegenerative diseases.
The Bailey lab investigates the use of adeno-associated viral (AAV) vectors for therapeutic gene delivery for neurological disorders. Our lab uses both gene-replacement and gene-silencing approaches, optimizes AAV vector delivery to the nervous system, and facilitates the translation of these therapies into human testing. This work requires the use of cellular and rodent models to investigate the disease pathogenesis, vector efficacy, and identification of biomarkers for human testing. Our main research interests are:
- Engineering AAV vectors
- Developing gene therapies for genetic pediatric disorders
- Developing gene therapies for neurodegenerative diseases
- Selective targeting of AAV vectors to the central and peripheral nervous systems
- Translating gene therapies to clinical trials